Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

Trials show Androxal superior in Secondary Hypogonadism-Repros Therapeutics

29-Aug-2014

Repros Therapeutics reported top line ...

Amgen files evolocumab at FDA for treatment of High Cholesterol

29-Aug-2014

Amgen has announced the submission ...

Evolocumab success in YUKAWA-1 trial for patients with High Cardiovascular Risk and High Cholesterol- Amgen

29-Aug-2014

Amgen has announced that the Phase ...

FDA approves Promacta for severe aplastic Anaemia-GSK

28-Aug-2014

The FDA has approved a supplemental ...

EU Commission approves Velphoro for treatment of Hyperphosphatemia in CKD patients- Vifor Fresenius Renal Pharma

28-Aug-2014

Velphoro (sucroferric oxyhydroxide) ...

European Commission approves Daklinza for treatment of chronic Hepatitis C- BMS

28-Aug-2014

Bristol-Myers Squibb Company ...

Medtronic acquires Sapiens Steering Brain Stimulation for $200 million

28-Aug-2014

Medtronic, Inc. announced that it has ...

Recent Updates

Drugs

Clinical Guidelines

Management of patients with stroke: identification and management of dysphagia

Guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011

Hepatocellular carcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Myocardial infarction with ST-segment elevation: The acute management of myocardial infarction with ST-segment elevation

Medical Journals

Phenotypic predictors of response to oral glucocorticosteroids in severe asthma

IL10 polymorphisms influence neonatal immune responses, atopic dermatitis, and wheeze at age 3 years

The effectiveness of footwear as an intervention to prevent or to reduce biomechanical risk factors associated with diabetic foot ulceration: A systematic review

Use of ?-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy

epgonline.org Social